In GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., the United States Court of Appeals for the Federal Circuit (CAFC) on Friday reversed a district court’s motion for judgment as a matter of law (JMOL) for Teva, finding that Teva was liable for induced infringement of GlaxoSmithKline’s ( Read More>>
Categories Courts, District Courts, Federal Circuit, IP News, IPWatchdog Articles, Litigation, Patents, CAFC, carvedilol, generic drugs, gsk, hatch-waxman, innovation, intellectual property, patent, patent infringement, Patent Litigation, patents, reissue patent, teva
